# Livagen (KEDA Tetrapeptide): Complete Research Profile — Khavinson Liver & Chromatin Decondensation Bioregulator (2026)
Livagen is a synthetic tetrapeptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, primarily targeting liver (hepatic) tissue, but uniquely distinguished within the Khavinson bioregulator catalog for being the most extensively studied peptide for chromatin decondensation effects — the reversal of age-related gene silencing through chromatin remodeling.
With the amino acid sequence Lys-Glu-Asp-Ala (KEDA), Livagen belongs to the KE-family and is the subject of a landmark 2002 study that directly demonstrated chromatin decondensation and ribosomal gene reactivation in lymphocytes from elderly human donors — one of the most concrete demonstrations of epigenetic anti-aging activity in the Khavinson research program.
This profile covers Livagen's molecular data, liver biology, the chromatin decondensation mechanism, the key published research including the 2002 Lezhava study, and hepatoprotective evidence in preclinical models.
> Disclaimer: This article is for educational and research purposes only. Livagen is not an approved therapeutic agent. Nothing herein constitutes medical advice.
---
What Is Livagen?
Livagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (one-letter code: KEDA), systematically named H-Lys-Glu-Asp-Ala-OH.
Within the Khavinson KE-family, Livagen occupies the Ala C-terminal position, distinguishing it from other family members:
- •Vesugen (KED): Vascular endothelium
- •Livagen (KEDA): Liver/chromatin ← this article
- •Testagen (KEDG): Testicular tissue
- •Prostamax (KEDP): Prostate gland
The alanine (Ala) residue is among the simplest amino acids — small, non-polar, and highly flexible — which may contribute to Livagen's relatively non-specific chromatin decondensation effects that appear to extend beyond liver tissue to lymphocytes and other cell types, unlike the more tissue-restricted profiles of some other bioregulators.
Key Characteristics at a Glance
| Property | Detail |
|---|---|
| Full name | Livagen / KEDA Tetrapeptide |
| Amino acid sequence | Lys-Glu-Asp-Ala (H-Lys-Glu-Asp-Ala-OH) |
| One-letter code | KEDA |
| Molecular weight | ~461.47 Da |
| Molecular formula | C₁₈H₃₁N₅O₉ |
| Peptide length | Tetrapeptide (4 amino acids) |
| Origin | Liver bioregulator — Khavinson research program |
| Primary target tissue | Liver (hepatocytes), lymphocytes (chromatin studies) |
| Proposed mechanism | Chromatin decondensation, ribosomal gene activation, epigenetic gene expression modulation |
| Research focus areas | Chromatin aging reversal, hepatoprotection, chromatin structure in aged cells |
---
The Khavinson Bioregulator Framework
For the full framework discussion, see: Khavinson Bioregulatory Peptides: Complete Guide.
Livagen's unique position in the class:
Livagen holds a special place among Khavinson bioregulatory peptides because it is the compound for which the chromatin decondensation mechanism is most directly and extensively documented at the cellular level in human material. The 2002 Lezhava study — discussed in detail below — provides arguably the most compelling direct evidence for the epigenetic mechanism underlying the entire bioregulator class.
This distinguishes Livagen from other bioregulators whose gene expression effects are inferred from downstream functional changes (proliferation, apoptosis, specific protein levels) rather than directly measured at the chromatin level.
---
Liver Tissue: What Livagen Is Designed to Target
Hepatocyte Biology
The liver is the most metabolically complex organ in the human body, performing over 500 distinct physiological functions. Hepatocytes — the primary parenchymal cells of the liver — make up approximately 80% of liver cell number and perform the vast majority of hepatic functions:
Metabolic functions:
- •Carbohydrate metabolism (glycogen synthesis/breakdown, gluconeogenesis)
- •Lipid metabolism (fatty acid synthesis, beta-oxidation, VLDL production, cholesterol synthesis)
- •Protein metabolism (albumin synthesis, clotting factor synthesis, amino acid metabolism)
- •Xenobiotic metabolism (Phase I/II detoxification via cytochrome P450 system)
Secretory functions:
- •Bile production and secretion
- •Secretion of plasma proteins (albumin, fibrinogen, alpha-globulins)
- •Production of IGF-1 (insulin-like growth factor 1) under GH stimulation
Storage functions:
- •Glycogen storage (primary carbohydrate reserve)
- •Fat-soluble vitamin storage (A, D, E, K)
- •Iron storage (ferritin/hemosiderin)
Hepatocytes are characterized by extraordinarily high levels of protein synthesis — consistent with Livagen's proposed mechanism of activating ribosomal genes that support translational capacity.
Age-Related Hepatic Changes
Aging produces progressive changes in liver function:
- •Reduced hepatic blood flow: 30–40% decrease in hepatic perfusion with age
- •Decreased metabolic enzyme activity: CYP450 activity declines, reducing drug clearance capacity
- •Impaired regeneration: Reduced hepatocyte proliferative response after partial hepatectomy
- •Increased hepatic fat: Non-alcoholic fatty liver disease (NAFLD) prevalence rises sharply with age
- •Chromatin changes: Progressive heterochromatinization in aging hepatocytes silences metabolic gene programs
---
The Landmark Chromatin Decondensation Research
The 2002 Lezhava Study: Key Evidence for Epigenetic Aging Reversal
The most significant published study involving Livagen is the 2002 research by Khavinson and Lezhava published in Bulletin of Experimental Biology and Medicine:
"Effects of Livagen peptide on chromatin activation in lymphocytes from old people" (PubMed PMID: 12533768)
Study design:
- •Lymphocytes (white blood cells) were isolated from elderly human donors (ages 70–80)
- •Cells were treated with Livagen (KEDA) in culture
- •Chromatin structure was analyzed using silver staining methods that visualize the transcriptional activity of ribosomal RNA genes (rDNA) located in the nucleolus organizing regions (NORs) of chromosomes
Key findings:
1. Ribosomal gene activation: Livagen treatment significantly increased the number of active ribosomal RNA gene clusters (NORs) in treated lymphocytes compared to untreated aged cells
2. Chromatin decondensation: Direct visualization showed that Livagen induced decondensation of pericentromeric heterochromatin — the dense, transcriptionally silent chromatin at chromosome centromeres — in cells from elderly donors
3. Age reversal of chromatin pattern: The chromatin pattern in Livagen-treated aged cells shifted toward patterns more characteristic of younger cells, with more open (euchromatic) chromatin and more active NORs
4. Specificity for aged cells: Effects were more pronounced in aged cell donors than in young donors, suggesting Livagen specifically counteracts age-related chromatin condensation rather than non-specifically disrupting chromatin structure
Why this matters:
This study is particularly important because it:
- •Used human cells (rather than animal or cell line models)
- •Demonstrated direct chromatin visualization (not just functional proxies)
- •Showed effects at the level of the ribosomal gene cluster — the cellular machinery for protein synthesis that declines with age
- •Provided morphological evidence of heterochromatin decondensation
- •Connected the observed chromatin changes directly to age-related silencing reversal
This constitutes one of the most direct demonstrations in the published Khavinson literature that bioregulatory peptides can produce measurable, specific epigenetic changes in aged human tissue — consistent with the theoretical framework underlying the entire class.
A 2003 Follow-Up Study
A follow-up study by the same group (PubMed PMID: 15085253, 2003) — "Effects of short peptides on lymphocyte chromatin in senile subjects" — extended these findings by comparing chromatin effects across multiple Khavinson peptides (including Vilon, Epitalon, Cortagen, and Livagen) and confirmed that the chromatin activation effect is shared across the bioregulatory peptide class, with Livagen among the most potent.
---
Hepatoprotective Research
The 2020 Comprehensive Review
A 2020 review by Kuznik, Khavinson, and Linkova published in peer-reviewed literature evaluated the hepatoprotective (liver-protecting) properties of Khavinson bioregulatory peptides in preclinical models.
The review covered experimental models including:
- •Liver fibrosis models: Carbon tetrachloride (CCl₄)-induced hepatic fibrosis in rodents
- •Acute hepatitis models: Drug-induced acute liver injury
- •Chronic hepatitis models: Viral and chemical chronic hepatic injury
Multiple Khavinson peptides including Livagen demonstrated protective effects in these models, with endpoints including:
- •Reduced hepatic fibrosis markers (collagen deposition, hydroxyproline content)
- •Improved liver enzyme profiles (ALT, AST)
- •Preservation of hepatic architecture
- •Reduced oxidative stress markers
Proposed Hepatic Mechanism
In liver tissue specifically, Livagen's chromatin decondensation mechanism is proposed to:
1. Restore expression of hepatic detoxification enzymes (CYP450 family)
2. Reactivate metabolic gene programs silenced by age-related chromatin condensation
3. Support hepatocyte protein synthesis capacity through ribosomal gene activation
4. Reduce age-associated hepatic inflammation through restoration of anti-inflammatory gene expression
---
Comparison With Other Bioregulators
Within the Khavinson Family
| Peptide | Sequence | Chromatin Evidence | Primary Tissue |
|---|---|---|---|
| Livagen | KEDA | Strongest (direct NOR/heterochromatin visualization in human cells) | Liver |
| Vilon | KE | Documented (chromatin studies) | Thymus |
| Epitalon | AEDG | Documented (chromatin studies) | Pineal |
| Cortagen | AEDP | Documented (chromatin studies) | Cerebral cortex |
| Prostamax | KEDP | Included in class-wide studies | Prostate |
Livagen's chromatin evidence is the most directly visualized and extensively published within the Khavinson catalog, making it the reference compound for the epigenetic mechanism of the entire class.
Versus Other Hepatoprotective Peptides
BPC-157: 15-amino acid peptide with documented hepatoprotective effects in rodent models through angiogenesis promotion and receptor-mediated pathways; mechanistically distinct from Livagen's epigenetic approach.
Thymosin β-4: Has some liver fibrosis research, acting through actin regulation and anti-inflammatory mechanisms; receptor-mediated vs. Livagen's chromatin approach.
---
Frequently Asked Questions
Is Livagen the same as Vesugen with one extra amino acid?
Livagen (KEDA) and Vesugen (KED) share the KED tripeptide core, with Livagen adding Ala at the C-terminus. While they share structural similarity, their proposed tissue targets differ significantly: Vesugen for vascular endothelium, Livagen for liver tissue. The additional Ala residue appears to shift tissue targeting toward hepatic cells.
Why was Livagen tested in lymphocytes if it targets liver?
Lymphocytes are practical cells for chromatin research — easily isolated from blood samples, with well-characterized chromosome structures and accessible chromatin. The chromatin decondensation mechanism documented in lymphocytes is proposed to reflect a general property of Livagen across tissues, including its primary target (liver). Lymphocyte chromatin studies served as a convenient test system for mechanistic investigation.
How significant is ribosomal gene activation?
Ribosomal RNA genes encode the ribosomal RNA components of the cell's protein synthesis machinery. Reactivating these genes in aged cells — where they tend to be progressively silenced — directly increases translational capacity and protein synthesis output. This has broad implications for cellular function, as virtually all cellular activities depend on adequate protein synthesis.
---
Summary
Livagen (KEDA tetrapeptide) is the Khavinson bioregulatory peptide targeting liver tissue, and uniquely, the compound for which the epigenetic chromatin decondensation mechanism is most directly demonstrated in published human cell research. The landmark 2002 Lezhava study showing direct ribosomal gene activation and pericentromeric heterochromatin decondensation in lymphocytes from elderly donors represents one of the strongest mechanistic publications in the entire Khavinson bioregulator literature.
Beyond its mechanistic significance, Livagen has hepatoprotective evidence in preclinical liver disease models, supporting its proposed role as a liver-targeting bioregulatory peptide.
For researchers studying epigenetic aging biology, chromatin remodeling, or hepatic aging, Livagen offers both a mechanistically well-supported model compound and a scientifically interesting research target.
---
Further Reading:
- •Prostamax (KEDP Tetrapeptide): Complete Research Profile — Khavinson Prostate Bioregulator (2026)
- •Cardiogen: Complete Research Profile — Khavinson Cardiac Bioregulatory Tetrapeptide (AEDR) for Heart Tissue Research (2026)
- •Testagen (KEDG Tetrapeptide): Complete Research Profile — Khavinson Testicular & Reproductive Bioregulator (2026)
- •Vesugen (KED Tripeptide): Complete Research Profile — Khavinson Vascular Endothelium Bioregulator (2026)
- •Half-Life Calculator
---
Related Articles:
- •Khavinson Bioregulatory Peptides: Complete Guide
- •Vilon (KE): Thymus & Immune Bioregulator
- •Vesugen (KED): Vascular Endothelium Bioregulator
This article is for educational and research purposes only. Livagen is not an approved therapeutic agent. Nothing herein constitutes medical advice.